Full side-by-side comparison — 2026
Data as of May 20, 2026 · Updated automatically
| Metric | JNJ | PFE |
|---|---|---|
| Current Price | 230.48 | 25.87 |
| Previous Close | 229.32 | 25.79 |
| Metric | JNJ | PFE |
|---|---|---|
| Trailing P/E | 26.24 | 19.34 |
| Forward P/E | 17.84 | 8.93 |
| Price / Book | 6.72 | 1.67 |
| Price / Sales | 5.66 | 2.28 |
| EV / EBITDA | 16.86 | 7.71 |
| Metric | JNJ | PFE |
|---|---|---|
| Dividend Yield | 0.0229% | 0.0680% |
| Dividend Rate (Annual) | 5.20 | 1.72 |
| 5-Year Avg Yield | 2.77% | 4.48% |
| Payout Ratio | 0.5952% | 1.3054% |
| Metric | JNJ | PFE |
|---|---|---|
| Beta (Volatility) | 0.26 | 0.31 |
| Debt / Equity | 67.73 | 71.60 |
| Quick Ratio | 0.69 | 0.85 |
| Current Ratio | 1.03 | 1.25 |
| Metric | JNJ | PFE |
|---|---|---|
| Revenue Growth | 0.0990% | 0.0540% |
| Earnings Growth | -0.5290% | -0.1010% |
| Return on Equity | 0.2642% | 0.0831% |
| Revenue / Share | 40.02 | 11.13 |
| Trailing EPS | 8.64 | 1.31 |
| Forward EPS | 12.71 | 2.84 |
| Metric | JNJ | PFE |
|---|---|---|
| Analyst Mean Target | 252.96 | 29.19 |
| Analyst High Target | 285.00 | 36.00 |
| Analyst Low Target | 155.00 | 24.00 |
Pfizer Inc. (PFE) leads on 10 of 19 comparable metrics.
Pfizer Inc. is the stronger pick for value investors, while Johnson & Johnson may appeal to growth investors.
This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.
JNJ's earnings declined 53% — declining profits may mean current valuation metrics (PE, payout ratio) are misleading.
Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in …
View JNJ details →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, …
View PFE details →Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.
Start Free Portfolio